Suppr超能文献

中、日、欧、美药典与 S. Hoffmann 提出的 2-2-2 理论模型在兔热原试验中升温解读的比较。

Comparison of temperature rise interpretations in the rabbit pyrogen test among Chinese, Japanese, European, and United States pharmacopeias and 2-2-2 theoretical models proposed by S. Hoffmann.

机构信息

National Institute for the Control of Pharmaceutical and Biological Products, Beijing, People's Republic of China.

出版信息

Innate Immun. 2011 Oct;17(5):486-95. doi: 10.1177/1753425910384754. Epub 2010 Nov 18.

Abstract

Although the rabbit pyrogen test is one of the crucial methods included in each pharmacopeia to evaluate the safety of parenteral medicine, the experimental procedures and pyrogen result judgment algorithms (PRJAs) are still greatly different from one another. In the first stage of testing, original data of 879 batches from a total of 2637 rabbits in our laboratory were judged by PRJAs in the Chinese Pharmacopoeia 2005 III, the Japanese Pharmacopoeia XIV, the Japanese Pharmacopoeia XV, the European Pharmacopeia 6.0, the United States Pharmacopoeia 32 NF27 and two theoretical models proposed by S. Hoffmann, respectively. The results were analyzed to evaluate the effects of various PRJAs. It was shown that: (i) the significant differences in the results judged by various pharmacopeias and Hoffmann's theoretical models were mainly due to the PRJAs and the great differences in PRJAs should be harmonized throughout the world based on balance of reducing animal use and guaranteeing the safety of medicines; (ii) it is better to use PRJAs that depend on the threshold of the sum of temperature rise of all tested rabbits than those that depend on the number of rabbits that are over the threshold of temperature rise of individual rabbit according to clinical proof and the experimental data; and (iii) the PRJA of the Japanese Pharmacopoeia XV has obvious advantages when the total suspicious rate of samples was less than 10%. Additionally, a new PRJA designed for reducing the additional experiment stages and animal consumption is promoted for evaluation.

摘要

虽然兔热原试验是各版药典中用于评估注射用药品安全性的重要方法之一,但实验程序和热原结果判断算法(PRJAs)仍存在很大差异。在测试的第一阶段,我们实验室的 2637 只兔子中的 879 批原始数据分别采用中国药典 2005 年版第三部、日本药典 14 版、日本药典 15 版、欧洲药典 6.0 版、美国药典 32 版 NF27 和 S. Hoffmann 提出的两种理论模型的 PRJAs 进行了判断。结果进行了分析,以评估各种 PRJAs 的效果。结果表明:(i)各种药典和 Hoffmann 理论模型判断结果的显著差异主要是由于 PRJAs 不同,应根据减少动物使用和保证药品安全性的平衡,在全球范围内协调 PRJAs;(ii)根据临床证据和实验数据,最好使用依赖于所有测试兔子体温升高总和的阈值的 PRJAs,而不是依赖于个体兔子体温升高阈值的兔子数量的 PRJAs;(iii)当样品总可疑率小于 10%时,日本药典 15 版的 PRJA 具有明显优势。此外,还提出了一种新的 PRJA,旨在减少额外的实验阶段和动物消耗,以供评估。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验